Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership [Seeking Alpha]
Pacific Biosciences of California, Inc. (PACB)
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacificbiosciences.com
Company Research
Source: Seeking Alpha
Despite 10% growth since 2015, dilution eroded shareholder value; pivot possible with 25% growth through 2029 and improved financing mix. Stand-alone and peer analyses show optimism despite further dilution risks, with brokers forecasting a 178% upside. Other risks include fast-moving technological changes in a competitive industry. It's a gradual Speculative Buy, with an expected return of +29%. Investment Thesis for Pacific Biosciences PacBio's ( NASDAQ: PACB ) expansion with Revio and Onso sequencing technologies positions the company for market and technology gains. It promises a move away from previous dilution with a revenue growth forecast of 25% by 2029. Despite the risks from technological changes and further dilution, analysts see an upside potential of 178%. However, a gradual, Speculative Buy with an expected return of 29% is more reasonable. Company Insights PacBio is involved in developing and producing advanced sequencing solutions. Sequencing refers to d
Show less
Read more
Impact Snapshot
Event Time:
PACB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PACB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PACB alerts
High impacting Pacific Biosciences of California, Inc. news events
Weekly update
A roundup of the hottest topics
PACB
News
- Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks [Yahoo! Finance]Yahoo! Finance
- Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- PacBio moved to Neutral at JPMorgan after guidance cut [Seeking Alpha]Seeking Alpha
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating.MarketBeat
PACB
Earnings
- 2/15/24 - Beat
PACB
Sec Filings
- 4/16/24 - Form 8-K
- 4/15/24 - Form PRE
- 4/11/24 - Form POSASR
- PACB's page on the SEC website